Charlotte obtained a Ph.D. in Molecular Oncology at Ludwig-Maximilians-University in Munich. Here, she discovered a new pathway that enhances the action of PARP inhibitors, targeted cancer drugs for the treatment of breast and ovarian cancer. Next to her Ph.D. in academia, she helped to establish the scientific pipeline of an early-stage biotech start-up, which exposed her to the early steps of drug development and resulted in a joint patent application.

At the BioBusiness Summer School, she will give insights into her transition from academia into the biotech industry, her work as a scientist in a fast-growing scale-up environment and is open to any questions you may have.